This is a multi-centre randomised, double blind, placebo-controlled, parallel group trial of the effectiveness of the nocturnal use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in adults with poorly-controlled, severe allergic asthma
The trial is assessing whether a new treatment device might help to reduce the frequency of severe asthma attacks in patients with allergic asthma.
Asthma affects over 5 million people in the UK. Half a million of these have a severe form of the condition. Potentially life threatening attacks, known as exacerbations, are a frequent occurrence. Current treatment options to reduce the frequency of these exacerbations are limited.
The LASER trial will evaluate the effectiveness of a new treatment – Temperature Controlled Laminar Airflow (TLA.) TLA is delivered by an Airsonett® machine. The machine is used overnight in the patient’s home at the bedside. The machine filters allergy particles from the air overnight, allowing patients to sleep and ‘rest’ their lungs.